Regenerative medical assistance such as cell and gene therapy has the potential to regenerate damaged tissues and whole organs by replacing damaged groups of tissues, encouraging the body’s own repair mechanisms. There is a considerable excitement among key stakeholders due to the encouraging development in regenerative medicines. The expectation that cell and gene therapies are likely to offer substantial clinical gains and even cure fatal and debilitating diseases is driving vendors to invest in R&D.
Speaking of therapy, this blog will briefly touch upon the growth potential of the cell and gene therapies in treating several chronic and fatal morbidities.
Increasing Pool of Patients
The increased prevalence of several diseases and ailments, especially chronic ones is expected to drive the market. The following points highlight the potential of cell and gene therapies in treating several morbidities:
- They are used to treat several types of cancers such as leukemia, melanoma, lymphoma, multiple myeloma, and solid tumors
- They are helpful in curing bone-related disorders such as osteoarthritis, symptomatic defects of the articulating cartilage, and other bone-related deformities
- These therapies attend to cardiovascular diseases (CVDs)such as cardiac heart failure, decreased ejection fraction, myocardial infarction, and critical limb ischemia (CLI)
- They help to tend acute and chronic wounds due to burns, scars, sports injuries, accidents, pressure ulcers, and venous leg ulcers
According to the WHO, approximately 17 million new cancer cases and subsequent 9.6 million deaths were reported in 2018. The organization also estimated that one in five men and one in six women develop cancer during their lifetime across the globe, whereas one in eight men and one in 11 women lose their life due to this disorder. It also reported that around 180,000 deaths take place annually due to burns, especially in low- and middle-income countries. Hence, the rise in the target pool of patients with wounds, cancers, and other chronic ailments is expected to influence the cell and gene therapies market significantly.
Innovative Product Launches
Vendors are strategically focusing on the development and launch of innovative products to remain competitive in the market. Several key vendors heavily invest in R&D activities as they are likely to have significant market share globally owing to their continuous involvement in product innovations and launches. The launch of new products helps meet unfulfilled medical needs and benefits patients that do not respond to conventional therapies. A key vendor introduced chimeric antigen receptor T-cell therapy (CAR-T) to heal adult patients with relapsed or refractory (r/r) large B-cell lymphoma, hence the launch of these types of innovative products is expected to bolster the cell and gene therapies market.
The market generated over $1,000 million in the North American region in 2018. The growth in the geriatric patient population in North America is likely to be a major driver for the growth of the cell and gene therapies market. The US Census estimated that the number of people aged above 65 will be more than children by 2030. Moreover, approximately in every 3-minute one person in the US is diagnosed with blood cancer, while in every 9 minutes, one person in the US dies from blood cancer, therefore the increase in leukemia and lymphoma cases is expected to contribute to market growth. In Europe, the market generated over $410 million in 2018. Europe is likely to witness high growth due to the increasing prevalence of chronic diseases such as cancer, Diabetic foot ulcers (DFUs), pressure ulcers, and musculoskeletal disorders. The availability of reimbursement coverage in the UK, Germany, Spain, and France is expected to influence the market. APAC is expected to emerge a major contributor to the market during the forecast period. The high prevalence of cancer, osteoarthritis, burns and other chronic wounds as well as active efforts by companies to enter large markets such as India and China that have high potential for this therapy is expected to influence the growth of the APAC cell and gene therapies market.
- Gilead Sciences
- Spark Therapeutics
- Novartis AG
- Osiris Therapeutics
Looking for more information? Click Here
About Arizton Advisory & Intelligence
Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize fool proof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging
Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Call: +1-312-235-2040/+1 302 469 0707
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States